Key Takeaways
- Commercial questions exist during development—not only after approval.
- Endpoints, evidence and trial design can strengthen or weaken future adoption and access.
- Waiting until Phase III to introduce commercial thinking often reduces strategic options.
- The goal is not premature marketing; it is better development decisions.
One of the most consequential misunderstandings in emerging biotechnology is that commercialization begins when the commercial organization is hired.
In my experience, that framing arrives too late.
Clinical development decisions already shape positioning, physician confidence, payer evidence, patient identification and the feasibility of launch. Commercialization should therefore influence development—not as promotional interference, but as a disciplined set of questions about how an innovative therapy will reach patients.
What “Influence” Actually Means
Commercial influence does not mean marketing controls the protocol. It means leadership asks, early enough to matter:
- Which patients are diagnosed and reachable?
- What evidence will specialists require to change practice?
- What evidence will payers and institutions require to enable access?
- Where does the patient journey break down today?
- Which Centers of Excellence will shape standards of care?
These questions belong inside development strategy. They are core to biotech commercialization consulting.
Evidence Decisions Are Commercial Decisions
A statistically significant primary endpoint may still leave physicians uncertain about clinical meaningfulness, or leave payers without the health-economic context required for coverage.
For emerging companies, waiting until launch to discover missing evidence is expensive. The better approach is to identify evidence gaps while protocols, registries and companion studies can still address them.
Commercial Thinking Protects Optionality
Companies evaluating independent commercialization, partnership or acquisition benefit from understanding real commercialization requirements early. Without that understanding, strategic alternatives are compared with incomplete information.
Related reading: Should a biotech commercialize independently or partner? and When should commercial planning begin?.
Discipline, Not Distraction
Scientific excellence remains essential. Commercial thinking does not replace it.
It ensures that scientific investment is directed toward a therapy the healthcare system can adopt, reimburse and deliver.
About Joseph McCoy
Joseph McCoy is Founder and Principal Consultant of PharmaKonsult and an executive commercial strategy advisor with more than three decades of pharmaceutical and biotechnology commercial leadership experience across neuroscience, rare disease, endocrinology, institutional healthcare and specialty pharmaceuticals.
